A 40-year-old male with severe alcohol use disorder has completed detoxification and is motivated for pharmacotherapy. He has a history of multiple prior relapses, partly attributed to medication nonadherence with daily oral naltrexone. He also reports a remote history of opioid use disorder, currently in sustained remission for 3 years with no opioid agonist therapy. The PMHNP discusses long-acting injectable naltrexone (Vivitrol). Which of the following is the most critical consideration before administering the first injection?